Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 66Lymphoma, Follicular 21Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Mantle-Cell 10Lymphoma 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 7Neoplasms, Plasma Cell 6Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Smoldering Multiple Myeloma 3Neoplasms 3Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Hematologic Diseases 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

Rituximab 1Lenalidomide 1CT-P10 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Composite Lymphoma × Lenalidomide × 90 days × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡